Multifarious roles of sialic acids in immunity

Annals of the New York Academy of Sciences

Volumn 1253, Issue 1, 2012, Pages 16-36

  Varki, Ajit ^a   Gagneux, Pascal ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Evolution; Immunity; Selectins; Sialic acids; Sialidases; Siglecs

Indexed keywords

ANTIBODY; AUTOANTIGEN; CD15S ANTIGEN; CD22 ANTIGEN; CD24 ANTIGEN; CD33 ANTIGEN; CD34 ANTIBODY; CD45 ANTIGEN; CD52 ANTIGEN; CD56 ANTIGEN; CD60A ANTIGEN; CD60B ANTIGEN; CD60C ANTIGEN; CD62E ANTIGEN; COMPLEMENT FACTOR H; HEMAGGLUTININ; IMMUNOGLOBULIN G ANTIBODY; LEUKOSIALIN; LIGAND; MICROBIAL ENZYME; POLYSIALIC ACID; RECEPTOR; SELECTIN; SIALIC ACID; SIALIDASE; SIALOADHESIN; SIALOGLYCAN ANTIBODY; SIGLEC; UNCLASSIFIED DRUG; UNINDEXED DRUG; XENO AUTOANTIGEN;

ACETYLATION; ARTICLE; BACTERIOPHAGE; BIOSYNTHESIS; BLOOD GROUP; CAT; CELL ACTIVATION; CELL MIGRATION; FEMALE GENITAL SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; INNATE IMMUNITY; LEUKOCYTE; MICROORGANISM; MOLECULAR EVOLUTION; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REGULATORY MECHANISM;

INVERTEBRATA; VERTEBRATA;

EID: 84859416185     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06517.x     Document Type: Article

References (234)

1. Schauer, R., G.V. Srinivasan, D. Wipfler, et al. 2011. O-Acetylated sialic acids and their role in immune defense. Adv. Exp. Med. Biol. 705: 525-548.
2. Schauer, R. 2009. Sialic acids as regulators of molecular and cellular interactions. Curr. Opin. Struct. Biol. 19: 507-514.
3. Lewis, A.L., N. Desa, E.E. Hansen, et al. 2009. Innovations in host and microbial sialic acid biosynthesis revealed by phylogenomic prediction of nonulosonic acid structure. Proc. Natl. Acad. Sci. USA 106: 13552-13557.
4. Varki, A. & R. Schauer. 2009. Sialic Acids. In Essentials of Glycobiology. 2nd ed. A. Varki, R.D. Cummings, J.D. Esko, H.H. Freeze, P. Stanley, C.R. Bertozzi, G.W. Hart & M.E. Etzler, Eds.: 199-218. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, NY.
5. Severi, E., D.W. Hood & G.H. Thomas. 2007. Sialic acid utilization by bacterial pathogens. Microbiology 153: 2817-2822.
6. Troy, F.A. 1992. Polysialylation: from bacteria to brains. Glycobiology 2: 5-23.
7. Vimr, E.R., K.A. Kalivoda, E.L. Deszo & S.M. Steenbergen. 2004. Diversity of microbial sialic acid metabolism. Microbiol. Mol. Biol. Rev. 68: 132-153.
8. Byrne, B., G.G. Donohoe & R. O'Kennedy. 2007. Sialic acids: carbohydrate moieties that influence the biological and physical properties of biopharmaceutical proteins and living cells. Drug Discov. Today 12: 319-326.
9. Rutishauser, U. 1998. Polysialic acid at the cell surface: biophysics in service of cell interactions and tissue plasticity. J. Cell. Biochem. 70: 304-312.
10. Collins, B.E., O. Blixt, A.R. DeSieno, et al. 2004. Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact. Proc. Natl. Acad. Sci. USA 101: 6104-6109.
11. Pilatte, Y., J. Bignon & C.R. Lambré. 1993. Sialic acids as important molecules in the regulation of the immune system: pathophysiological implications of sialidases in immunity. Glycobiology 3: 201-218.
12. Gahmberg, C.G. & L.C. Andersson. 1977. Selective radioactive labeling of cell surface sialoglycoproteins by periodate-tritiated borohydride. J. Biol. Chem. 252: 5888-5894.
13. Dehoux-zenou, S.M., M. Guenounou, H. Zinbi, et al. 1987. Behavior of aldehyde moieties involved in the activation of suppressor cells by sodium periodate. J. Immunol. 138: 1157-1163.
14. Jacobs, C.L., K.J. Yarema, L.K. Mahal, et al. 2000. Metabolic labeling of glycoproteins with chemical tags through unnatural sialic acid biosynthesis. Methods Enzymol. 327: 260-275.
15. Du, J., M.A. Meledeo, Z. Wang, et al. 2009. Metabolic glycoengineering: sialic acid and beyond. Glycobiology 19: 1382-1401.
16. Prescher, J.A. & C.R. Bertozzi. 2006. Chemical technologies for probing glycans. Cell 126: 851-854.
17. Varki, A. 2010. Colloquium paper: uniquely human evolution of sialic acid genetics and biology. Proc. Natl. Acad. Sci. USA 107(Suppl. 2): 8939-8946.
18. Fearon, D.T. 1978. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc. Natl. Acad. Sci. USA 75: 1971-1975.
19. Pangburn, M.K. & H.J. Muller-Eberhard. 1978. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. Proc. Natl. Acad. Sci. USA 75: 2416-2420.
20. Meri, S. & M.K. Pangburn. 1990. Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid /polyanion binding site on factor H. Proc. Natl. Acad. Sci. USA 87: 3982-3986.
21. Ram, S., A.K. Sharma, S.D. Simpson, et al. 1998. A novel sialic acid-binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae. J. Exp. Med. 187: 743-752.
22. Varki, A. 2011. Since there are PAMPs and DAMPs, there must be SAMPs? Glycan "self-associated molecular patterns" dampen innate immunity, but pathogens can mimic them. Glycobiology 21: 1121-1124.
23. Johnston, J.W., N.P. Coussens, S. Allen, et al. 2008. Characterization of the N-acetyl-5-neuraminic acid-binding site of the extracytoplasmic solute receptor (SiaP) of nontypeable haemophilus influenzae strain 2019. J. Biol. Chem. 283: 855-865.
24. Ram, S., L.A. Lewis & S. Agarwal. 2011. Meningococcal group w-135 and y capsular polysaccharides paradoxically enhance activation of the alternative pathway of complement. J. Biol. Chem. 286: 8297-8307.
25. Zipfel, P.F., C. Skerka, J. Hellwage, et al. 2002. Factor H family proteins: on complement, microbes and human diseases. Biochem. Soc. Trans. 30: 971-978.
26. Kajander, T., M.J. Lehtinen, S. Hyvarinen, et al. 2011. Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc. Natl. Acad. Sci. USA 108: 2897-2902.
27. Morgan, H.P., J. Jiang, A.P. Herbert, et al. 2011. Crystallographic determination of the disease-associated T1184R variant of complement regulator factor H. Acta. Crystallogr. D Biol. Crystallogr. 67: 593-600.
28. Shaughnessy, J., S. Ram, A. Bhattacharjee, et al. 2011. Molecular characterization of the interaction between sialylated Neisseria gonorrhoeae and factor H. J. Biol. Chem. 286: 22235-22242.
29. Atkinson, J.P. & T.H. Goodship. 2007. Complement factor H and the hemolytic uremic syndrome. J. Exp. Med. 204: 1245-1248.
30. Donoso, L.A., T. Vrabec & H. Kuivaniemi. 2010. The role of complement Factor H in age-related macular degeneration: a review. Surv. Ophthalmol. 55: 227-246.
31. Nydegger, U.E., D.T. Fearon & K.F. Austen. 1978. Autosomal locus regulates inverse relationship between sialic acid content and capacity of mouse erythrocytes to activate human alternative complement pathway. Proc. Natl. Acad. Sci. USA 75: 6078-6082.
32. Shi, W.X., R. Chammas, N.M. Varki, et al. 1996. Sialic acid 9-O-acetylation on murine erythroleukemia cells affects complement activation, binding to I-type lectins, and tissue homing. J. Biol. Chem. 271: 31526-31532.
33. Arming, S., D. Wipfler, J. Mayr, et al. 2011. The human Cas1 protein: a sialic acid-specific O-acetyltransferase? Glycobiology 21: 553-564.
34. Kjaer, T.R., A.G. Hansen, U.B. Sorensen, et al. 2011. Investigations on the pattern recognition molecule M-ficolin: quantitative aspects of bacterial binding and leukocyte association. J. Leukoc. Biol. 90: 425-437.
35. Honore, C., S. Rorvig, T. Hummelshoj, et al. 2010. Tethering of Ficolin-1 to cell surfaces through recognition of sialic acid by the fibrinogen-like domain. J. Leukoc. Biol. 88: 145-158.
36. Gout, E., V. Garlatti, D.F. Smith, et al. 2010. Carbohydrate recognition properties of human ficolins: glycan array screening reveals the sialic acid-binding specificity of M-ficolin. J. Biol. Chem. 285: 6612-6622.
37. Rosen, S.D., M.S. Singer, T.A. Yednock & L.M. Stoolman. 1985. Involvement of sialic acid on endothelial cells in organ-specific lymphocyte recirculation. Science 228: 1005-1007.
38. McEver, R.P. 1991. Selectins: novel receptors that mediate leukocyte adhesion during inflammation. Thromb. Haemost. 65: 223-228.
39. Cummings, R.D. & D.F. Smith. 1992. The selectin family of carbohydrate-binding proteins: structure and importance of carbohydrate ligands for cell adhesion. BioEssays 14: 849-856.
40. Rosen, S.D. 1993. L-selectin and its biological ligands. Histochemistry 100: 185-191.
41. Varki, A. 1994. Selectin ligands. Proc. Natl. Acad. Sci. USA 91: 7390-7397.
42. Lasky, L.A. 1995. Selectin-carbohydrate interactions and the initiation of the inflammatory response. Annu. Rev. Biochem. 64: 113-139.
43. Picker, L.J., R.A. Warnock, A.R. Burns, et al. 1991. The neutrophil selectin LECAM-1 presents carbohydrate ligands to the vascular selectins ELAM-1 and GMP-140. Cell 66: 921-933.
44. Zhou, Q., K.L. Moore, D.F. Smith, et al. 1991. The selectin GMP-140 binds to sialylated, fucosylated lactosaminoglycans on both myeloid and nonmyeloid cells. J. Cell Biol. 115: 557-564.
45. Tyrrell, D., P. James, N. Rao, et al. 1991. Structural requirements for the carbohydrate ligand of E-selectin. Proc. Natl. Acad. Sci. USA 88: 10372-10376.
46. Handa, K., E.D. Nudelman, M.R. Stroud, et al. 1991. Selectin GMP-140 (CD62; PADGEM) binds to sialosyl-Lea and sialosyl-Lex, and sulfated glycans modulate this binding. Biochem. Biophys. Res. Commun. 181: 1223-1230.
47. Berg, E.L., J. Magnani, R.A. Warnock, et al. 1992. Comparison of L-selectin and E-selectin ligand specificities: the L-selectin can bind the E-selectin ligands sialyl Lex and sialyl Lea. Biochem. Biophys. Res. Commun. 184: 1048-1055.
48. Foxall, C., S.R. Watson, D. Dowbenko, et al. 1992. The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl Lewisx oligosaccharide. J. Cell Biol. 117: 895-902.
49. Larsen, G.R., D. Sako, T.J. Ahern, et al. 1992. P-selectin and E-selectin. Distinct but overlapping leukocyte ligand specificities. J. Biol. Chem. 267: 11104-11110.
50. Moore, K.L., N.L. Stults, S. Diaz, et al. 1992. Identification of a specific glycoprotein ligand for P-selectin (CD62) on myeloid cells. J. Cell Biol. 118: 445-456.
51. Yeh, J.C., N. Hiraoka, B. Petryniak, et al. 2001. Novel sulfated lymphocyte homing receptors and their control by a core1 extension beta1, 3-N-acetylglucosaminyltransferase. Cell 105: 957-969.
52. Leppänen, A., P. Mehta, Y.B. Ouyang, et al. 1999. A novel glycosulfopeptide binds to P-selectin and inhibits leukocyte adhesion to P-selectin. J. Biol. Chem. 274: 24838-24848.
53. Larkin, M., T.J. Ahern, M.S. Stoll, et al. 1992. Spectrum of sialylated and nonsialylated fuco-oligosaccharides bound by the endothelial-leukocyte adhesion molecule E-selectin. Dependence of the carbohydrate binding activity on E-selectin density. J. Biol. Chem. 267: 13661-13668.
54. Norgard-Sumnicht, K.E., N.M. Varki & A. Varki. 1993. Calcium-dependent heparin-like ligands for L-selectin in nonlymphoid endothelial cells. Science 261: 480-483.
55. Nelson, R.M., O. Cecconi, W.G. Roberts, et al. 1993. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 82: 3253-3258.
56. Norgard, K.E., H. Han, L. Powell, et al. 1993. Enhanced interaction of L-selectin with the high endothelial venule ligand via selectively oxidized sialic acids. Proc. Natl. Acad. Sci. USA 90: 1068-1072.
57. Rosen, S.D. 2004. Ligands for L-selectin: homing, inflammation, and beyond. Annu. Rev. Immunol. 22: 129-156.
58. Crocker, P.R. & S. Gordon. 1986. Properties and distribution of a lectin-like hemagglutinin differentially expressed by murine stromal tissue macrophages. J. Exp. Med. 164: 1862-1875.
59. Crocker, P.R., S. Kelm, C. Dubois, et al. 1991. Purification and properties of sialoadhesin, a sialic acid-binding receptor of murine tissue macrophages. EMBO J 10: 1661-1669.
60. Stamenkovic, I., D. Sgroi, A. Aruffo, et al. 1991. The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and alpha 2-6 sialyltransferase, CD75, on B cells. Cell 66: 1133-1144.
61. Sgroi, D., A. Varki, S. Braesch-Andersen & I. Stamenkovic. 1993. CD22, a B cell-specific immunoglobulin superfamily member, is a sialic acid-binding lectin. J. Biol. Chem. 268: 7011-7018.
62. Powell, L.D., D. Sgroi, E.R. Sjoberg, et al. 1993. Natural ligands of the B cell adhesion molecule CD22beta carry N-linked oligosaccharides with alpha-2, 6-linked sialic acids that are required for recognition. J. Biol. Chem. 268: 7019-7027.
63. Powell, L.D. & A. Varki. 1994. The oligosaccharide binding specificities of CD22beta, a sialic acid-specific lectin of B cells. J. Biol. Chem. 269: 10628-10636.
64. Crocker, P.R., S. Mucklow, V. Bouckson, et al. 1994. Sialoadhesin, a macrophage sialic acid-binding receptor for haemopoietic cells with 17 immunoglobulin-like domains. EMBO J. 13: 4490-4503.
65. Kelm, S., A. Pelz, R. Schauer, et al. 1994. Sialoadhesin, myelin-associated glycoprotein and CD22 define a new family of sialic acid-dependent adhesion molecules of the immunoglobulin superfamily. Curr. Biol. 4: 965-972.
66. Freeman, S.D., S. Kelm, E.K. Barber & P.R. Crocker. 1995. Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 85: 2005-2012.
67. Kelm, S., R. Schauer & P.R. Crocker. 1996. The sialoadhesins: a family of sialic acid-dependent cellular recognition molecules within the immunoglobulin superfamily. Glycoconjugate J. 13: 913-926.
68. Collins, B.E., M. Kiso, A. Hasegawa, et al. 1997. Binding specificities of the sialoadhesin family of I-type lectins: sialic acid linkage and substructure requirements for binding of myelin-associated glycoprotein, Schwann cell myelin protein, and sialoadhesin. J. Biol. Chem. 272: 16889-16895.
69. Powell, L.D. & A. Varki. 1995. I-type lectins. J. Biol. Chem. 270: 14243-14246.
70. Crocker, P.R., E.A. Clark, M. Filbin, et al. 1998. Siglecs: a family of sialic-acid binding lectins [letter]. Glycobiology 8: v.
71. Angata, T., E.H. Margulies, E.D. Green & A. Varki. 2004. Large-scale sequencing of the CD33-related Siglec gene cluster in five mammalian species reveals rapid evolution by multiple mechanisms. Proc. Natl. Acad. Sci. USA 101: 13251-13256.
72. Angata, T. 2006. Molecular diversity and evolution of the Siglec family of cell-surface lectins. Mol. Divers. 10: 555-566.
73. Crocker, P.R., J.C. Paulson & A. Varki. 2007. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 7: 255-266.
74. von Gunten, S. & B.S. Bochner. 2008. Basic and clinical immunology of Siglecs. Ann. N. Y. Acad. Sci. 1143: 61-82.
75. Cao, H., B. de Bono, K. Belov, et al. 2009. Comparative genomics indicates the mammalian CD33rSiglec locus evolved by an ancient large-scale inverse duplication and suggests all Siglecs share a common ancestral region. Immunogenetics 61: 401-417.
76. O'Reilly, M.K. & J.C. Paulson. 2010. Multivalent ligands for Siglecs. Methods Enzymol. 478: 343-363.
77. Cao, H. & P.R. Crocker. 2011. Evolution of CD33-related Siglecs: regulating host immune functions and escaping pathogen exploitation? Immunology 132: 18-26.
78. Park, C.S. & B.S. Bochner. 2011. Potential targeting of Siglecs, mast cell inhibitory receptors, in interstitial cystitis. Int. Neurourol. J. 15: 61-63.
79. Pillai, S., I.A. Netravali, A. Cariappa & H. Mattoo. 2011. Siglecs and immune regulation. Annu. Rev. Immunol. 30. [Epub ahead of print.] PMID: 22224769.
80. Yu, Z.B., M. Maoui, L.T. Wu, et al. 2001. mSiglec-E, a novel mouse CD33-related Siglec (sialic acid-binding immunoglobulin-like lectin) that recruits Src homology 2 (SH2)-domain-containing protein tyrosine phosphatases SHP-1 and SHP-2. Biochem. J. 353: 483-492.
81. Whitney, G., S.L. Wang, H. Chang, et al. 2001. A new Siglec family member, Siglec-10, is expressed in cells of the immune system and has signaling properties similar to CD33. Eur. J. Biochem. 268: 6083-6096.
82. Angata, T., S.C. Kerr, D.R. Greaves, et al. 2002. Cloning and characterization of human Siglec-11. A recently evolved signaling molecule that can interact with SHP-1 and SHP-2 and is expressed by tissue macrophages, including brain microglia. J. Biol. Chem. 277: 24466-24474.
83. Avril, T., H. Floyd, F. Lopez, et al. 2004. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells. J. Immunol. 173: 6841-6849.
84. Nitschke, L. 2009. CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol. Rev. 230: 128-143.
85. Liu, Y., G.Y. Chen & P. Zheng. 2009. CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns. Trends Immunol. 30: 557-561.
86. Avril, T., S.D. Freeman, H. Attrill, et al. 2005. Siglec-5 (CD170) can mediate inhibitory signalling in the absence of immunoreceptor tyrosine-based inhibitory motif phosphorylation. J. Biol. Chem. 280: 19843-19851.
87. Mitsuki, M., K. Nara, T. Yamaji, et al. 2010. Siglec-7 mediates nonapoptotic cell death independently of its immunoreceptor tyrosine-based inhibitory motifs in monocytic cell line U937. Glycobiology 20: 395-402.
88. Angata, T., T. Hayakawa, M. Yamanaka, et al. 2006. Discovery of Siglec-14, a novel sialic acid receptor undergoing concerted evolution with Siglec-5 in primates. FASEB J. 20: 1964-1973.
89. Angata, T., Y. Tabuchi, K. Nakamura & M. Nakamura. 2007. Siglec-15: an immune system Siglec conserved throughout vertebrate evolution. Glycobiology 17: 838-846.
90. Yasui, K., T. Angata, N. Matsuyama, et al. 2011. Detection of anti-Siglec-14 alloantibodies in blood components implicated in nonhaemolytic transfusion reactions. Br. J. Haematol. 153: 794-796.
91. Hiruma, Y., T. Hirai & E. Tsuda. 2011. Siglec-15, a member of the sialic acid-binding lectin, is a novel regulator for osteoclast differentiation. Biochem. Biophys. Res. Commun. 409: 424-429.
92. Cao, H., U. Lakner, B. de Bono, et al. 2008. SIGLEC16 encodes a DAP12-associated receptor expressed in macrophages that evolved from its inhibitory counterpart SIGLEC11 and has functional and non-functional alleles in humans. Eur. J. Immunol. 38: 2303-2315.
93. Varki, A. & T. Angata. 2006. Siglecs-the major subfamily of I-type lectins. Glycobiology 16: 1R-27R.
94. Crocker, P.R. & P. Redelinghuys. 2008. Siglecs as positive and negative regulators of the immune system. Biochem. Soc. Trans. 36: 1467-1471.
95. O'Reilly, M.K. & J.C. Paulson. 2009. Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol. Sci. 30: 240-248.
96. Varki, A. 2009. Natural ligands for CD33-related Siglecs? Glycobiology 19: 810-812.
97. Jandus, C., H.U. Simon & S. von Gunten. 2011. Targeting Siglecs: a novel pharmacological strategy for immuno- and glycotherapy. Biochem. Pharmacol. 82: 323-332.
98. Magesh, S., H. Ando, T. Tsubata, et al. 2011. High-affinity ligands of Siglec receptors and their therapeutic potentials. Curr. Med. Chem. 18: 3537-3550.
99. Razi, N. & A. Varki. 1998. Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes. Proc. Natl. Acad. Sci. USA 95: 7469-7474.
100. Kawasaki, Y., A. Ito, D.A. Withers, et al. 2010. Ganglioside DSGb5, preferred ligand for Siglec-7, inhibits NK cell cytotoxicity against renal cell carcinoma cells. Glycobiology 20: 1373-1379.
101. Blixt, O., S. Han, L. Liao, et al. 2008. Sialoside analogue arrays for rapid identification of high affinity Siglec ligands. J. Am. Chem. Soc. 130: 6680-6681.
102. Cui, L., P.I. Kitov, G.C. Completo, et al. 2011. Supramolecular complexing of membane Siglec CD22 mediated by a polyvalent heterobifunctional ligand that templates on IgM. Bioconjug. Chem. 22: 546-550.
103. Vinson, M., P.A. Van der Merwe, S. Kelm, et al. 1996. Characterization of the sialic acid-binding site in sialoadhesin by site-directed mutagenesis. J. Biol. Chem. 271: 9267-9272.
104. Van der Merwe, P.A., P.R. Crocker, M. Vinson, et al. 1996. Localization of the putative sialic acid-binding site on the immunoglobulin superfamily cell-surface molecule CD22. J. Biol. Chem. 271: 9273-9280.
105. Crocker, P.R., M. Vinson, S. Kelm & K. Drickamer. 1999. Molecular analysis of sialoside binding to sialoadhesin by NMR and site-directed mutagenesis. Biochem. J. 341: 355-361.
106. Angata, T. & A. Varki. 2000. Cloning, characterization, and phylogenetic analysis of Siglec-9, a new member of the CD33-related group of Siglecs: evidence for co-evolution with sialic acid synthesis pathways. J. Biol. Chem. 275: 22127-22135.
107. Angata, T., N.M. Varki & A. Varki. 2001. A second uniquely human mutation affecting sialic acid biology. J. Biol. Chem. 276: 40282-40287.
108. Mandal, C. 1990. Sialic acid-binding lectins. Experientia 46: 433-441.
109. Traving, C. & R. Schauer. 1998. Structure, function and metabolism of sialic acids. Cell Mol Life Sci 54: 1330-1349.
110. Isa, P., C.F. Arias & S. Lopez. 2006. Role of sialic acids in rotavirus infection. Glycoconj. J. 23: 27-37.
111. Gee, G.V., A.S. Dugan, N. Tsomaia, et al. 2006. The role of sialic acid in human polyomavirus infections. Glycoconj. J. 23: 19-26.
112. Lehmann, F., E. Tiralongo & J. Tiralongo. 2006. Sialic acid-specific lectins: occurrence, specificity and function. Cell Mol. Life Sci. 63: 1331-1354.
113. Taylor, G. 1996. Sialidases: structures, biological significance and therapeutic potential. Curr. Opin. Struct. Biol. 6: 830-837.
114. von Itzstein, M. 2007. The war against influenza: discovery and development of sialidase inhibitors. Nat. Rev. Drug Discov. 6: 967-974.
115. Herrler, G., R. Rott, H.D. Klenk, et al. 1985. The receptor-destroying enzyme of influenza C virus is neuraminate-O-acetylesterase. EMBO J 4: 1503-1506.
116. Rogers, G.N., G. Herrler, J.C. Paulson & H.D. Klenk. 1986. Influenza C virus uses 9-O-acetyl-N-acetylneuraminic acid as a high affinity receptor determinant for attachment to cells. J. Biol. Chem. 261: 5947-5951.
117. Vlasak, R., M. Krystal, M. Nacht & P. Palese. 1987. The influenza C virus glycoprotein (HE) exhibits receptor-binding (hemagglutinin) and receptor-destroying (esterase) activities. Virology 160: 419-425.
118. Vlasak, R., W. Luytjes, J. Leider, et al. 1988. The E3 protein of bovine coronavirus is a receptor-destroying enzyme with acetylesterase activity. J. Virol. 62: 4686-4690.
119. Herrler, G. & H.-D. Klenk. 1991. Structure and function of the HEF glycoprotein of influenza C virus. Adv. Virus Res. 40: 213-234.
120. Pleschka, S., H.D. Klenk & G. Herrler. 1995. The catalytic triad of the influenza C virus glycoprotein HEF esterase: characterization by site-directed mutagenesis and functional analysis. J. Gen. Virol. 76: 2529-2537.
121. Cornelissen, L.A.H.M., C.M.H. Wierda, d. M.F.J. van, et al. 1997. Hemagglutinin-esterase: a novel structural protein of torovirus. J. Virol. 71: 5277-5286.
122. Wurzer, W.J., K. Obojes & R. Vlasak. 2002. The sialate-4-O-acetylesterases of coronaviruses related to mouse hepatitis virus: a proposal to reorganize group 2 Coronaviridae. J. Gen. Virol. 83: 395-402.
123. de Groot, R.J. 2006. Structure, function and evolution of the hemagglutinin-esterase proteins of corona- and toroviruses. Glycoconj. J. 23: 59-72.
124. Schwegmann-Wessels, C. & G. Herrler. 2006. Sialic acids as receptor determinants for coronaviruses. Glycoconj. J. 23: 51-58.
125. Langereis, M.A., A.L. van Vliet, W. Boot & R.J. de Groot. 2010. Attachment of mouse hepatitis virus to O-acetylated sialic acid is mediated by hemagglutinin-esterase and not by the spike protein. J. Virol. 84: 8970-8974.
126. Orlandi, P.A., F.W. Klotz & J.D. Haynes. 1992. A malaria invasion receptor, the 175-kilodalton erythrocyte binding antigen of Plasmodium falciparum recognizes the terminal Neu5Ac(alpha 2-3)Gal- sequences of glycophorin A. J. Cell Biol. 116: 901-909.
127. Dolan, S.A., J.L. Proctor, D.W. Alling, et al. 1994. Glycophorin B as an EBA-175 independent Plasmodium falciparum receptor of human erythrocytes. Mol. Biochem. Parasitol. 64: 55-63.
128. DeLuca, G.M., M.E. Donnell, D.J. Carrigan & D.P. Blackall. 1996. Plasmodium falciparum merozoite adhesion is mediated by sialic acid. Biochem. Biophys. Res. Commun. 225: 726-732.
129. Baum, J., R.H. Ward & D.J. Conway. 2002. Natural selection on the erythrocyte surface. Mol. Biol. Evol. 19: 223-229.
130. Byres, E., A.W. Paton, J.C. Paton, et al. 2008. Incorporation of a non-human glycan mediates human susceptibility to a bacterial toxin. Nature 456: 648-652.
131. Roggentin, P., R. Schauer, L.L. Hoyer & E.R. Vimr. 1993. The sialidase superfamily and its spread by horizontal gene transfer. Mol. Microbiol. 9: 915-921.
132. Vimr, E., C. Lichtensteiger & S. Steenbergen. 2000. Sialic acid metabolism's dual function in Haemophilus influenzae. Mol. Microbiol. 36: 1113-1123.
133. Johnston, J.W., A. Zaleski, S. Allen, et al. 2007. Regulation of sialic acid transport and catabolism in Haemophilus influenzae. Mol. Microbiol. 66: 26-39.
134. Trappetti, C., A. Kadioglu, M. Carter, et al. 2009. Sialic acid: a preventable signal for pneumococcal biofilm formation, colonization, and invasion of the host. J. Infect. Dis. 199: 1497-1505.
135. Corfield, A.P., W.M. Sander, R.W. Veh, et al. 1986. The action of sialidases on substrates containing O-acetylsialic acids. Biol. Chem. Hoppe Seyler 367: 433-439.
136. Matzinger, P. 2002. The danger model: a renewed sense of self. Science 296: 301-305.
137. Chen, G.Y. & G. Nunez. 2010. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 10: 826-837.
138. Miyagi, T., T. Wada, K. Yamaguchi & K. Hata. 2004. Sialidase and malignancy: a minireview. Glycoconj. J. 20: 189-198.
139. Magesh, S., V. Savita, S. Moriya, et al. 2009. Human sialidase inhibitors: design, synthesis, and biological evaluation of 4-acetamido-5-acylamido-2-fluoro benzoic acids. Bioorg. Med. Chem. 17: 4595-4603.
140. Monti, E., E. Bonten, A. D'Azzo, et al. 2010. Sialidases in vertebrates a family of enzymes tailored for several cell functions. Adv. Carbohydr. Chem. Biochem. 64: 403-479.
141. Carrillo, M.B., C.M. Milner, S.T. Ball, et al. 1997. Cloning and characterization of a sialidase from the murine histocompatibility-2 complex: low levels of mRNA and a single amino acid mutation are responsible for reduced sialidase activity in mice carrying the Neu1a allele. Glycobiology 7: 975-986.
142. Rottier, R.J., E. Bonten & A. D'Azzo. 1998. A point mutation in the neu-1 locus causes the neuraminidase defect in the SM/J mouse. Hum. Mol. Genet. 7: 313-321.
143. Van, d.S.A., E. Bonten & A. D'Azzo. 1998. Transport of human lysosomal neuraminidase to mature lysosomes requires protective protein cathepsin A. EMBO J. 17: 1588-1597.
144. Amith, S.R., P. Jayanth, S. Franchuk, et al. 2009. Dependence of pathogen molecule-induced toll-like receptor activation and cell function on Neu1 sialidase. Glycoconj. J. 26: 1197-1212.
145. Hinek, A., T.D. Bodnaruk, S. Bunda, et al. 2008. Neuraminidase-1, a subunit of the cell surface elastin receptor, desialylates and functionally inactivates adjacent receptors interacting with the mitogenic growth factors PDGF-BB and IGF-2. Am. J. Pathol. 173: 1042-1056.
146. Feng, C., L. Zhang, L. Almulki, et al. 2011. Endogenous PMN sialidase activity exposes activation epitope on CD11b/CD18 which enhances its binding interaction with ICAM-1. J. Leukoc. Biol. 90: 313-321.
147. Amith, S.R., P. Jayanth, S. Franchuk, et al. 2010. Neu1 desialylation of sialyl alpha-2, 3-linked beta-galactosyl residues of TOLL-like receptor 4 is essential for receptor activation and cellular signaling. Cell. Signal. 22: 314-324.
148. Nan, X., I. Carubelli & N.M. Stamatos. 2007. Sialidase expression in activated human T lymphocytes influences production of IFN-{gamma}. J. Leukoc. Biol. 81: 284-296.
149. Seyrantepe, V., A. Iannello, F. Liang, et al. 2010. Regulation of phagocytosis in macrophages by neuraminidase 1. J. Biol. Chem. 285: 206-215.
150. Toscano, M.A., G.A. Bianco, J.M. Ilarregui, et al. 2007. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat. Immunol. 8: 825-834.
151. Monti, E., M.T. Bassi, N. Papini, et al. 2000. Identification and expression of NEU3, a novel human sialidase associated to the plasma membrane. Biochem. J. 349: 343-351.
152. Wang, Y., K. Yamaguchi, T. Wada, et al. 2002. A close association of the ganglioside-specific sialidase Neu3 with caveolin in membrane microdomains. J. Biol. Chem. 277: 26252-26259.
153. Vimr, E. & C. Lichtensteiger. 2002. To sialylate, or not to sialylate: that is the question. Trends Microbiol. 10: 254-257.
154. Schoenhofen, I.C., D.J. McNally, J.R. Brisson & S.M. Logan. 2006. Elucidation of the CMP-pseudaminic acid pathway in Helicobacter pylori: synthesis from UDP-N-acetylglucosamine by a single enzymatic reaction. Glycobiology 16: 8C-14C.
155. Schoenhofen, I.C., E. Vinogradov, D.M. Whitfield, et al. 2009. The CMP-legionaminic acid pathway in Campylobacter: biosynthesis involving novel GDP-linked precursors. Glycobiology 19: 715-725.
156. Marques, M.B., D.L. Kasper, M.K. Pangburn & M.R. Wessels. 1992. Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect. Immun. 60: 3986-3993.
157. Campagnari, A.A., M.R. Gupta, K.C. Dudas, et al. 1987. Antigenic diversity of lipooligosaccharides of nontypable Haemophilus influenzae. Infect. Immun. 55: 882-887.
158. Jones, C., M. Virji & P.R. Crocker. 2003. Recognition of sialylated meningococcal lipopolysaccharide by Siglecs expressed on myeloid cells leads to enhanced bacterial uptake. Mol. Microbiol. 49: 1213-1225.
159. Avril, T., E.R. Wagner, H.J. Willison & P.R. Crocker. 2006. Sialic acid-binding immunoglobulin-like lectin 7 mediates selective recognition of sialylated glycans expressed on Campylobacter jejuni lipooligosaccharides. Infect. Immun. 74: 4133-4141.
160. Khatua, B., A. Ghoshal, K. Bhattacharya, et al. 2010. Sialic acids acquired by Pseudomonas aeruginosa are involved in reduced complement deposition and Siglec mediated host-cell recognition. FEBS Lett. 584: 555-561.
161. Carlin, A.F., S. Uchiyama, Y.C. Chang, et al. 2009. Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response. Blood 113: 3333-3336.
162. Vanderheijden, N., P.L. Delputte, H.W. Favoreel, et al. 2003. Involvement of sialoadhesin in entry of porcine reproductive and respiratory syndrome virus into porcine alveolar macrophages. J. Virol. 77: 8207-8215.
163. Rempel, H., C. Calosing, B. Sun & L. Pulliam. 2008. Sialoadhesin expressed on IFN-induced monocytes binds HIV-1 and enhances infectivity. PLoS ONE 3: e1967.
164. Jiang, H.R., L. Hwenda, K. Makinen, et al. 2006. Sialoadhesin promotes the inflammatory response in experimental autoimmune uveoretinitis. J. Immunol. 177: 2258-2264.
165. Oetke, C., M.C. Vinson, C. Jones & P.R. Crocker. 2006. Sialoadhesin-deficient mice exhibit subtle changes in B- and T-cell populations and reduced immunoglobulin m levels. Mol. Cell. Biol. 26: 1549-1557.
166. Ip, C.W., A. Kroner, P.R. Crocker, et al. 2007. Sialoadhesin deficiency ameliorates myelin degeneration and axonopathic changes in the CNS of PLP overexpressing mice. Neurobiol. Dis. 25: 105-111.
167. Wu, C., U. Rauch, E. Korpos, et al. 2009. Sialoadhesin-positive macrophages bind regulatory T cells, negatively controlling their expansion and autoimmune disease progression. J. Immunol. 182: 6508-6516.
168. Hallenbeck, P.C., E.R. Vimr, F. Yu, et al. 1987. Purification and properties of a bacteriophage-induced endo-N-acetylneuraminidase specific for poly-alpha-2, 8-sialosyl carbohydrate units. J. Biol. Chem. 262: 3553-3561.
169. Gerardy-Schahn, R., A. Bethe, T. Brennecke, et al. 1995. Molecular cloning and functional expression of bacteriophage PK1E-encoded endoneuraminidase Endo NE. Mol. Microbiol. 16: 441-450.
170. Cieslewicz, M.J., D. Chaffin, G. Glusman, et al. 2005. Structural and genetic diversity of group B streptococcus capsular polysaccharides. Infect. Immun. 73: 3096-3103.
171. Mushtaq, N., M.B. Redpath, J.P. Luzio & P.W. Taylor. 2004. Prevention and cure of systemic Escherichia coli K1 infection by modification of the bacterial phenotype. Antimicrob. Agents Chemother. 48: 1503-1508.
172. Waldor, M.K. & D.I. Friedman. 2005. Phage regulatory circuits and virulence gene expression. Curr Opin Microbiol 8: 459-465.
173. Rutishauser, U. 2008. Polysialic acid in the plasticity of the developing and adult vertebrate nervous system. Nat. Rev. Neurosci. 9: 26-35.
174. Weinhold, B., R. Seidenfaden, I. Rockle, et al. 2005. Genetic ablation of polysialic acid causes severe neurodevelopmental defects rescued by deletion of the neural cell adhesion molecule. J. Biol. Chem. 280: 42971-42977.
175. Bax, M., S.J. van Vliet, M. Litjens, et al. 2009. Interaction of polysialic acid with CCL21 regulates the migratory capacity of human dendritic cells. PLoS ONE 4: e6987.
176. Rey-Gallardo, A., C. Delgado-Martin, R. Gerardy-Schahn, et al. 2011. Polysialic acid is required for neuropilin-2a/b-mediated control of CCL21-driven chemotaxis of mature dendritic cells and for their migration in vivo. Glycobiology 21: 655-662.
177. Drake, P.M., J.K. Nathan, C.M. Stock, et al. 2008. Polysialic acid, a glycan with highly restricted expression, is found on human and murine leukocytes and modulates immune responses. J. Immunol. 181: 6850-6858.
178. Drake, P.M., C.M. Stock, J.K. Nathan, et al. 2009. Polysialic acid governs T-cell development by regulating progenitor access to the thymus. Proc. Natl. Acad. Sci. USA 106: 11995-12000.
179. Gagneux, P. & A. Varki. 1999. Evolutionary considerations in relating oligosaccharide diversity to biological function. Glycobiology 9: 747-755.
180. Bishop, J.R. & P. Gagneux. 2007. Evolution of carbohydrate antigens-microbial forces shaping host glycomes? Glycobiology 17: 23R-34R.
181. An, G., B. Wei, B. Xia, et al. 2007. Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived O-glycans. J. Exp. Med. 204: 1417-1429.
182. Ghate, A.A. & G.M. Air. 1999. Influenza type B neuraminidase can replace the function of type A neuraminidase. Virology 264: 265-277.
183. Adams, J.H., B.K. Sim, S.A. Dolan, et al. 1992. A family of erythrocyte binding proteins of malaria parasites. Proc. Natl. Acad. Sci. USA 89: 7085-7089.
184. Persson, K.E., F.J. McCallum, L. Reiling, et al. 2008. Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies. J. Clin. Invest. 118: 342-351.
185. Dalziel, M., S. Lemaire, J. Ewing, et al. 1999. Hepatic acute phase induction of murine beta-galactoside:alpha2, 6 sialyltransferase (ST6Gal I) is IL-6 dependent and mediated by elevation of Exon H-containing class of transcripts. Glycobiology 9: 1003-1008.
186. Schauer, R. 1985. Sialic acids and their role as biological masks. Trends Biochem. Sci. 10: 357-360.
187. Weiss, P. & G. Ashwell. 1989. The asialoglycoprotein receptor: properties and modulation by ligand. Prog. Clin. Biol. Res. 300: 169-184.
188. Braun, J.R., T.E. Willnow, S. Ishibashi, et al. 1996. The major subunit of the asialoglycoprotein receptor is expressed on the hepatocellular surface in mice lacking the minor receptor subunit. J. Biol. Chem. 271: 21160-21166.
189. Grewal, P.K., S. Uchiyama, D. Ditto, et al. 2008. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat. Med. 14: 648-655.
190. Elward, K. & P. Gasque. 2003. "Eat me" and "don't eat me" signals govern the innate immune response and tissue repair in the CNS: emphasis on the critical role of the complement system. Mol. Immunol. 40: 85-94.
191. Liu, F.T. 2000. Galectins: a new family of regulators of inflammation. Clin. Immunol. 97: 79-88.
192. Rabinovich, G.A., N. Rubinstein & M.A. Toscano. 2002. Role of galectins in inflammatory and immunomodulatory processes. Biochim. Biophys. Acta. Gen. Subj. 1572: 274-284.
193. Lau, K.S., E.A. Partridge, A. Grigorian, et al. 2007. Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell 129: 123-134.
194. Mendelsohn, R., P. Cheung, L. Berger, et al. 2007. Complex N-glycan and metabolic control in tumor cells. Cancer Res. 67: 9771-9780.
195. Bi, S. & L.G. Baum. 2009. Sialic acids in T cell development and function. Biochim. Biophys. Acta 1790: 1599-1610.
196. Zhuo, Y. & S.L. Bellis. 2011. Emerging role of alpha2, 6-sialic acid as a negative regulator of galectin binding and function. J. Biol. Chem. 286: 5935-5941.
197. Ideo, H., T. Matsuzaka, T. Nonaka, et al. 2011. Galectin-8-N-domain recognition mechanism for sialylated and sulfated glycans. J. Biol. Chem. 286: 11346-11355.
198. Yoshida, H., M. Teraoka, N. Nishi, et al. 2010. X-ray structures of human galectin-9 C-terminal domain in complexes with a biantennary oligosaccharide and sialyllactose. J. Biol. Chem. 285: 36969-36976.
199. Fukushi, Y., E. Nudelman, S.B. Levery, et al. 1986. A novel disialoganglioside (IV3NeuAcIII6NeuAcLc4) of human adenocarcinoma and the monoclonal antibody (FH9) defining this disialosyl structure. Biochemistry 25: 2859-2866.
200. Song, Y., K. Kitajima & Y. Inoue. 1993. Monoclonal antibody specific to alpha-2->3-linked deaminated neuraminyl beta-galactosyl sequence. Glycobiology 3: 31-36.
201. Cheresh, D.A., R.A. Reisfeld & A. Varki. 1984. O-acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic determinant. Science 225: 844-846.
202. Schauer, R., G.V. Srinivasan, B. Coddeville, et al. 2009. Low incidence of N-glycolylneuraminic acid in birds and reptiles and its absence in the platypus. Carbohydr. Res. 344: 1494-1500.
203. Irie, A., S. Koyama, Y. Kozutsumi, et al. 1998. The molecular basis for the absence of N-glycolylneuraminic acid in humans. J. Biol. Chem. 273: 15866-15871.
204. Chou, H.H., H. Takematsu, S. Diaz, et al. 1998. A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc. Natl. Acad. Sci. USA 95: 11751-11756.
205. Fujii, Y., H. Higashi, K. Ikuta, et al. 1982. Specificities of human heterophilic Hanganutziu and Deicher (H-D) antibodies and avian antisera against H-D antigen-active glycosphingolipids. Mol. Immunol. 19: 87-94.
206. Naiki, M., Y. Fujii, K. Ikuta, et al. 1982. Expression of Hanganutziu and Deicher type heterophile antigen on the cell surface of Marek's disease lymphoma. Adv. Exp. Med. Biol. 152: 445-456.
207. Tangvoranuntakul, P., P. Gagneux, S. Diaz, et al. 2003. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc. Natl. Acad. Sci. USA 100: 12045-12050.
208. Taylor, R.E., C.J. Gregg, V. Padler-Karavani, et al. 2010. Novel mechanism for the generation of human xeno-autoantibodies against the nonhuman sialic acid N-glycolylneuraminic acid. J. Exp. Med. 207: 1637-1646.
209. Merrick, J.M., K. Zadarlik & F. Milgrom. 1978. Characterization of the Hanganutziu-Deicher (serum-sickness) antigen as gangliosides containing N-glycolylneuraminic acid. Int. Arch. Allergy Appl. Immunol. 57: 477-480.
210. Higashi, H., M. Naiki, S. Matuo & K. Okouchi. 1977. Antigen of "serum sickness" type of heterophile antibodies in human sera: indentification as gangliosides with N-glycolylneuraminic acid. Biochem. Biophys. Res. Commun. 79: 388-395.
211. Ghaderi, D., S.A. Springer, F. Ma, et al. 2011. Sexual selection by female immunity against paternal antigens can fix loss of function alleles. Proc. Natl. Acad. Sci. USA 108: 17743-17748.
212. Sadler, J.E., J.C. Paulson & R.L. Hill. 1979. The role of sialic acid in the expression of human MN blood group antigens. J. Biol. Chem. 254: 2112-2119.
213. Uemura, K., D. Roelcke, Y. Nagai & T. Feizi. 1984. The reactivities of human erythrocyte autoantibodies anti-Pr2, anti-Gd, Fl and Sa with gangliosides in a chromatogram binding assay. Biochem. J. 219: 865-874.
214. Andrews, G.A., P.S. Chavey, J.E. Smith & L. Rich. 1992. N-glycolylneuraminic acid and N-acetylneuraminic acid define feline blood group A and B antigens. Blood 79: 2485-2491.
215. Bighignoli, B., T. Niini, R.A. Grahn, et al. 2007. Cytidine monophospho-N-acetylneuraminic acid hydroxylase (CMAH) mutations associated with the domestic cat AB blood group. BMC Genet. 8: 27.
216. Yamakawa, T., A. Suzuki & Y. Hashimoto. 1986. Genetic control of glycolipid expression. Chem. Phys. Lipids 42: 75-90.
217. Weiman, S., S. Uchiyama, F.Y. Lin, et al. 2010. O-acetylation of sialic acid on group B streptococcus inhibits neutrophil suppression and virulence. Biochem. J. 428: 163-168.
218. Kelm, S., R. Schauer, J.C. Manuguerra, et al. 1994. Modifications of cell surface sialic acids modulate cell adhesion mediated by sialoadhesin and CD22. Glycoconjugate J. 11: 576-585.
219. Sjoberg, E.R., L.D. Powell, A. Klein & A. Varki. 1994. Natural ligands of the B cell adhesion molecule CD22beta can be masked by 9-O-acetylation of sialic acids. J. Cell Biol. 126: 549-562.
220. Cariappa, A., H. Takematsu, H. Liu, et al. 2009. B cell antigen receptor signal strength and peripheral B cell development are regulated by a 9-O-acetyl sialic acid esterase. J. Exp. Med. 206: 125-138.
221. Pillai, S., A. Cariappa & S.P. Pirnie. 2009. Esterases and autoimmunity: the sialic acid acetylesterase pathway and the regulation of peripheral B cell tolerance. Trends Immunol. 30: 488-493.
222. Surolia, I., S.P. Pirnie, V. Chellappa, et al. 2010. Functionally defective germline variants of sialic acid acetylesterase in autoimmunity. Nature 466: 243-247.
223. Kniep, B., W.A. Flegel, H. Northoff & E.P. Rieber. 1993. CDw60 glycolipid antigens of human leukocytes: structural characterization and cellular distribution. Blood 82: 1776-1786.
224. Rieber, E.P. & G. Rank. 1994. CDw60: a marker for human CD8+ T helper cells. J. Exp. Med. 179: 1385-1390.
225. Fox, D.A., X. He, A. Abe, T. Hollander, et al. 2001. The T lymphocyte structure CD60 contains a sialylated carbohydrate epitope that is expressed on both gangliosides and glycoproteins. Immunol. Invest. 30: 67-85.
226. Malisan, F., L. Franchi, B. Tomassini, et al. 2002. Acetylation suppresses the proapoptotic activity of GD3 ganglioside. J. Exp. Med. 196: 1535-1541.
227. Birks, S.M., J.O. Danquah, L. King, et al. 2011. Targeting the GD3 acetylation pathway selectively induces apoptosis in glioblastoma. Neuro. Oncol. 13: 950-960.
228. Chen, H.Y. & A. Varki. 2002. O-acetylation of GD3: an enigmatic modification regulating apoptosis? J. Exp. Med. 196: 1529-1533.
229. Kaneko, Y., F. Nimmerjahn & J.V. Ravetch. 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313: 670-673.
230. Anthony, R.M. & J.V. Ravetch. 2010. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J. Clin. Immunol. 30(Suppl. 1): S9-S14.
231. Anthony, R.M., T. Kobayashi, F. Wermeling & J.V. Ravetch. 2011. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 475: 110-113.
232. Durandy, A., S.V. Kaveri, T.W. Kuijpers, M. Basta, et al. 2009. Intravenous immunoglobulins: understanding properties and mechanisms. Clin. Exp. Immunol. 158(Suppl. 1): 2-13.
233. von Gunten, S. & H.U. Simon. 2010. Cell death modulation by intravenous immunoglobulin. J. Clin. Immunol. 30(Suppl. 1): S24-S30.
234. Jones, M.B., M. Nasirikenari, L. Feng, et al. 2010. Role for hepatic and circulatory ST6Gal-1 sialyltransferase in regulating myelopoiesis. J. Biol. Chem. 285: 25009-25017.